urgent
need
develop
effect
vaccin
pneumon
plagu
highli
lethal
contagi
diseas
caus
gramneg
bacterium
yersinia
pesti
demonstr
novel
dna
vaccin
express
modifi
v
antigen
lcrv
pesti
human
tissu
plasminogen
activ
tpa
signal
sequenc
elicit
strong
vspecif
antibodi
respons
balbc
mice
tpav
dna
vaccin
protect
mice
intranas
challeng
lethal
dose
pesti
comparison
dna
vaccin
express
wild
type
v
antigen
much
less
effect
tpav
form
oligom
spontan
elicit
higher
antiv
antibodi
respons
immun
mice
suggest
increas
h
type
cellular
immun
respons
data
indic
antigen
engin
effect
induc
high
qualiti
protect
immun
respons
conform
sensit
antigen
result
support
optim
dna
vaccin
potenti
protect
bacteri
pathogen
gener
recogn
gramneg
bacterium
yersinia
pesti
pesti
caus
agent
plagu
among
agent
greatest
concern
respect
illegitim
use
bioterror
biolog
warfar
current
target
sever
vaccin
develop
effort
natur
pesti
endem
rodent
popul
mani
part
world
transmit
primarili
via
bite
infect
flea
caus
bubon
plagu
diseas
character
grossli
swollen
lymph
node
bubo
pestisbas
weapon
use
world
war
ii
employ
fleabas
transmiss
direct
infect
human
via
aerosol
thought
like
danger
mode
deliveri
produc
pneumon
plagu
contrast
bubon
plagu
pneumon
plagu
progress
rapidli
highli
transmiss
via
droplet
mucos
surfac
requir
extrem
prompt
therapeut
intervent
unless
appropri
antimicrobi
therapi
institut
h
onset
symptom
diseas
uniformli
fatal
featur
pneumon
plagu
coupl
potenti
use
antibiot
resist
pesti
argu
strongli
develop
vaccin
effect
prevent
mucos
transmiss
pesti
tool
biodefens
current
known
effect
clinic
plagu
vaccin
pneumon
plaqu
kill
whole
cell
kwc
plagu
vaccin
licens
certain
part
world
discontinu
kwc
plagu
vaccin
shown
effect
protect
pneumon
plagu
small
anim
studi
certain
recombin
protein
vaccin
advanc
stage
develop
demonstr
provid
variou
level
protect
pneumon
plagu
anim
model
vaccin
util
one
two
known
protect
antigen
fraction
lcrv
v
protein
form
capsul
believ
confer
resist
phagocytosi
possibl
form
aqueou
pore
membran
phagocyt
cell
interf
complementmedi
opson
shown
effect
vaccin
compon
sinc
mutant
pesti
strain
unabl
produc
antigen
remain
highli
virul
relianc
protect
vaccin
antigen
may
unwis
identif
new
protect
antigen
need
make
improv
multicompon
plagu
vaccin
lcrv
intracellular
protein
secret
pesti
appropri
condit
observ
bacteri
surfac
believ
particip
type
iii
secret
system
facilit
transloc
mani
yersinia
outer
protein
yop
host
cell
achiev
antihost
properti
shown
potent
immunogen
recombin
v
protein
subunit
vaccin
abl
induc
protect
igg
mous
model
either
combin
recombin
protein
activ
search
new
protect
antigen
pesti
instanc
pesti
protein
pla
proteas
play
import
role
determin
invas
natur
pesti
deliv
subcutan
variou
pla
mutant
produc
sustain
local
infect
without
caus
system
diseas
remain
highli
virul
given
intraven
pla
integr
outer
membran
protein
activ
site
expos
cell
surfac
thu
apriori
potenti
attract
vaccin
compon
dna
vaccin
technolog
offer
particular
util
search
safe
effect
vaccin
emerg
infecti
diseas
bioterror
time
develop
vaccin
new
genet
modifi
pathogen
great
valu
necessari
plasmid
construct
quickli
produc
purif
protein
requir
sinc
antigen
encod
dna
vaccin
express
vivo
allow
rapid
screen
optim
mani
altern
antigen
base
immunogen
protect
data
collect
anim
studi
signific
improv
made
recent
year
dna
vaccin
technolog
sever
dnabas
vaccin
enter
earli
phase
clinic
trial
howev
major
effort
dna
vaccin
studi
far
direct
pathogen
virus
like
actual
viral
infect
protein
encod
dna
vaccin
express
within
host
cell
henc
avail
present
via
class
major
histocompat
complex
mhc
pathway
elicit
viral
antigenspecif
cytotox
lymphocyt
ctl
respons
develop
dna
vaccin
bacteri
pathogen
explor
less
thoroughli
perhap
protect
immun
bacteri
infect
thought
heavili
depend
humor
immun
respons
although
abil
dna
vaccin
gener
specif
antibodi
well
document
potenti
dna
vaccin
induc
protect
level
antibodi
respons
acut
bacteri
infect
begun
recogn
previou
attempt
develop
dna
vaccin
base
pesti
v
antigen
met
limit
success
elicit
low
level
vspecif
antibodi
titer
provid
poor
protect
challeng
pesti
given
proteinbas
lcrv
formul
provid
good
protect
failur
cast
doubt
role
dnabas
approach
previou
dna
vaccin
studi
infecti
agent
demonstr
proper
leader
sequenc
import
induc
high
level
antibodi
respons
increas
solubl
antigen
product
mammalian
cell
system
particular
describ
molecular
approach
enhanc
secret
thu
immunogen
antigen
link
human
tissu
plasminogen
activ
tpa
leader
sequenc
n
terminu
protein
sinc
lcrv
gene
encod
typic
signal
peptid
focu
studi
determin
immunogen
lcrvbase
dna
vaccin
could
improv
engin
includ
signal
sequenc
tpa
report
vaccin
design
abl
elicit
high
level
antiv
antibodi
respons
protect
mice
lethal
dose
pesti
intranas
challeng
model
interestingli
tpav
antigen
strong
tendenc
form
oligom
examin
vitro
express
system
data
present
studi
confirm
import
includ
lcrv
compon
multigen
plagu
dna
formul
studi
demonstr
dna
vaccin
provid
much
lower
protect
pla
dna
vaccin
protect
current
design
pesti
strain
kim
prepar
grow
inocula
h
c
tryptos
blood
agar
base
difco
supplement
mm
cacl
without
addit
blood
bacteria
remov
plate
inocul
loop
resuspend
injectiongrad
pb
bacteria
count
suspens
correl
optic
densiti
od
number
bacteria
final
inocula
confirm
coloni
count
v
pla
gene
amplifi
pfu
polymeras
strategen
ca
three
virul
plasmid
pesti
respect
use
follow
primer
pair
v
gene
gtcgctccaagcttgctagcatgattagagccta
agtcacggatcctc
gene
gtcgctccaagcttgctagcatgaaaaaaatca
agtcacggatcc
pla
gene
gtcgctccaagcttgctagcatgaagaaaagt
gagcaggcctcaga
wild
type
insert
pcr
amplifi
plagu
dna
sequenc
directli
subclon
dna
vaccin
vector
immedi
cmv
promot
insert
addit
tpa
leader
sequenc
pcr
amplifi
pesti
gene
sequenc
subclon
vector
downstream
tpa
leader
sequenc
alreadi
includ
vector
leader
sequenc
frame
subclon
plagu
gene
insert
final
plagu
dna
vaccin
prepar
use
mega
purif
kit
made
qiagen
valencia
ca
prior
anim
immun
six
eight
week
old
femal
balbc
mice
purchas
tacon
farm
germantown
ny
hous
depart
anim
medicin
univers
massachusett
medic
school
umm
accord
iacuc
approv
protocol
anim
immun
helio
gene
gun
biorad
shave
abdomin
skin
previous
report
mous
first
receiv
three
monthli
immun
six
dna
shot
g
per
immun
blood
sampl
collect
periorbit
prior
first
immun
week
immun
analys
plaguespecif
antibodi
respons
fourth
dna
immun
dose
given
week
prior
challeng
see
result
section
pesti
antigenspecif
igg
respons
immun
mice
measur
elisa
use
individu
pool
mous
sera
anim
group
elisa
plate
coat
l
antigen
gml
harvest
cell
transient
transfect
plagu
dna
vaccin
plasmid
incub
overnight
c
serial
dilut
mous
sera
l
ad
well
assay
duplic
block
plate
incub
biotinyl
antimous
igg
dilut
l
per
well
follow
horseradish
peroxidaseconjug
streptavidin
dilut
final
develop
tetramethybenzidin
solut
l
per
well
reaction
stop
ad
l
h
plate
read
od
isotypespecif
elisa
conduct
describ
except
use
horseradish
peroxidas
hrp
conjug
goatantimous
southern
technolog
associ
al
dilut
concentr
vspecif
mous
calcul
standard
curv
use
known
amount
purifi
mous
igg
mice
challeng
two
week
fourth
immun
observ
twice
daili
morbid
mortal
intranas
instil
l
salin
solut
contain
lethal
dose
pesti
kim
strain
administ
nostril
ketamineanesthethet
mice
method
lead
rapid
infect
lethal
nonimmun
mice
day
ld
challeng
model
determin
cfu
pilot
challeng
studi
therefor
challeng
dose
current
studi
rang
ld
cfu
ld
cfu
challeng
studi
conduct
biosafeti
level
contain
facil
depart
anim
medicin
umm
statist
analys
perform
anim
surviv
use
fisher
exact
test
signific
consid
pvalu
cell
transient
transfect
calcium
phosphat
coprecipit
method
use
g
plasmid
dna
cell
dish
harvest
h
later
amount
transient
express
v
antigen
ng
protein
load
sdspolyacryamid
gel
electrophoresi
sdspage
transfer
onto
pvdf
membran
biorad
hercul
ca
block
overnight
c
block
buffer
iblock
pb
membran
incub
dilut
mous
sera
immun
correspond
dna
vaccin
wash
blot
incub
alkalin
phosphataseconjug
goat
antimous
igg
dilut
signal
detect
use
chemiluminesc
westernlight
kit
tropix
bedford
usa
tpav
sampl
prepar
presenc
urea
glycosyl
studi
peptid
nglycosidas
f
pngasef
new
england
biolab
beverli
usa
ad
denatur
sampl
prepar
supernat
transient
transfect
cell
accord
manufacturor
instruct
incub
overnight
c
sampl
load
onto
sdspage
analyz
western
blot
describ
two
version
dna
vaccin
design
three
pesti
antigen
lcrv
pla
fig
one
encod
wild
type
wt
protein
encod
modifi
version
ad
tissu
plasminogen
activ
tpa
leader
sequenc
lcrv
pla
definit
leader
sequenc
pla
hydrophob
region
near
nterminu
aa
left
unchang
current
design
gene
includ
natur
leader
sequenc
aa
also
unchang
keep
two
gene
design
compat
v
pla
pesti
gene
insert
incorpor
individu
dna
vaccin
vector
wide
use
broad
rang
dna
vaccin
studi
contain
cmv
immedi
earli
promot
intron
sequenc
bovin
growth
hormon
polya
tail
previous
report
pesti
antigenspecif
antibodi
respons
immun
mice
measur
four
week
third
monthli
dna
vaccin
lcrv
dna
vaccin
induc
high
titer
igg
antibodi
respons
respect
antigen
detect
elisa
fig
lcrv
dna
vaccin
induc
one
log
higher
antibodi
respons
dna
vaccin
lcrv
dna
vaccin
tpa
leader
sequenc
gave
higher
antibodi
respons
wild
type
counterpart
improv
fold
fig
rise
antiv
antibodi
respons
time
analyz
fig
tpav
dna
vaccin
abl
induc
sharp
increas
antibodi
respons
follow
singl
immun
wtv
dna
vaccin
requir
least
two
immun
produc
respons
similar
level
fig
signific
antipla
igg
antibodi
respons
detect
anim
immun
either
wtpla
tpapla
dna
vaccin
fig
poor
immunogen
pla
dna
vaccin
may
result
low
level
express
pla
bare
detect
cell
transient
transfect
either
pla
construct
test
elisa
western
blot
use
known
posit
rabbit
antipla
sera
data
shown
dna
vaccin
mice
describ
receiv
fourth
dna
immun
week
challeng
week
later
long
delay
third
fourth
immun
due
unavail
anim
room
plagu
challeng
anim
inocul
lethal
challeng
kim
strain
pesti
cfu
ld
deliv
intranas
rout
anim
receiv
vector
control
dna
pla
dna
plasmid
quickli
develop
easili
observ
sign
sick
rough
coat
hunch
huddl
postur
shiver
labor
breath
lethargi
within
first
h
postchalleng
die
within
three
four
day
fig
three
dna
vaccin
wtv
provid
partial
protect
anim
surviv
week
observ
fig
anim
surviv
partial
protect
group
usual
transient
minor
sign
sick
decreas
groom
last
day
hand
tpav
dna
vaccin
provid
protect
initi
studi
fig
significantli
anim
group
show
sign
sick
remain
activ
entir
two
week
superior
protect
provid
tpav
dna
vaccin
confirm
subsequ
studi
use
dose
escal
challeng
increas
size
anim
group
two
group
mice
receiv
three
monthli
immun
either
wtv
tpav
dna
vaccin
follow
immun
procedur
describ
materi
method
confirm
posit
antiv
antibodi
respons
elisa
dna
immun
anim
data
shown
fourth
dna
immun
given
week
anim
challeng
two
week
later
three
intranas
challeng
dose
given
vaccin
group
shown
fig
surviv
substanti
better
tpav
vaccin
mice
three
challeng
dose
level
challeng
dose
cfu
ld
cfu
ld
cfu
ld
respect
anim
receiv
wtv
dna
vaccin
surviv
three
challeng
dose
tabl
summar
result
challeng
studi
differ
surviv
tpav
wtv
statist
signific
p
p
first
two
challeng
dose
cfu
cfu
base
fisher
exact
test
third
challeng
cfu
less
signific
p
due
rel
small
sampl
size
combin
data
three
challeng
dose
surviv
rate
tpav
immun
anim
compar
surviv
wtv
dna
immun
anim
none
control
anim
surviv
even
lowest
challeng
dose
cfu
fig
tabl
supernat
cell
lysat
collect
cell
transient
transfect
either
wtv
tpav
dna
vaccin
analyz
western
blot
analysi
tpav
wtv
dna
construct
display
good
level
v
antigen
express
fig
howev
tpav
protein
show
higher
tendenc
form
dimer
tetram
addit
monom
wtv
protein
mainli
monom
form
reveal
sdspage
analysi
fig
transient
express
v
antigen
heat
treat
presenc
urea
oligomer
v
protein
convert
monom
fig
suggest
convent
sdspage
effici
complet
denatur
certain
protein
tpav
high
tendenc
form
oligom
tpa
leader
lead
express
secret
protein
mani
protein
glycosyl
part
intracellular
process
one
would
question
whether
lcrv
protein
express
tpav
construct
glycosyl
may
affect
structur
function
v
antigen
base
amino
acid
sequenc
v
protein
put
nglycosal
site
confirm
predict
compar
molecular
weight
tpav
protein
treatment
peptid
nglycosidas
f
pngasef
pngasef
amidas
cleav
link
amino
acid
asparagin
innermost
glcnac
high
mannos
hybrid
complex
oligosaccharid
nlink
glycoprotein
mice
per
group
first
challeng
studi
anim
follow
week
challeng
accumul
surviv
plot
compar
efficaci
vaccin
pair
wild
type
tpa
vector
alon
indic
chang
appar
molecular
weight
among
pngasef
treat
untreat
mock
treat
tpav
antigen
fig
posit
control
assay
spike
glycoprotein
sever
acut
respiratori
syndrom
associ
coronaviru
sarscov
show
reduc
molecular
weight
pngase
f
treatment
fig
summari
data
rule
nglycosyl
contribut
factor
oligom
structur
better
protect
induc
tpav
antigen
given
fact
tpav
induc
slightli
higher
antiv
igg
respons
wtv
dna
construct
fig
enhanc
product
secret
v
antigen
tpav
dna
construct
appear
significantli
improv
immunogen
v
antigen
therefor
effect
protect
afford
tpav
may
relat
qualiti
tpav
induc
immun
respons
lcrv
oligom
may
play
import
role
recent
report
qualit
differ
immun
respons
induc
tpav
wtv
dna
vaccin
demonstr
level
isotyp
antiv
igg
respons
anim
sera
immun
two
lcrvbase
vaccin
compar
antigen
induc
predominantli
antibodi
respons
fig
anim
monitor
week
intranas
challeng
expect
gene
gun
deliv
dna
immun
howev
tpav
dna
vaccin
group
display
larg
increas
nearli
titer
rel
wtv
dna
vaccin
group
fig
mice
increas
level
indic
h
type
immun
respons
fig
tpav
antigen
glycosyl
fulli
denatur
tpav
protein
transient
express
cell
subject
treatment
pngase
f
analyz
western
blot
untreat
mock
treat
tpav
sampl
includ
neg
control
pngase
f
treatment
fragment
sarscov
spike
protein
use
posit
control
might
play
critic
role
better
protect
provid
tpav
dna
vaccin
well
known
dna
vaccin
highli
effect
induct
cellmedi
respons
data
argu
strongli
dna
immun
also
effect
induct
protect
antibodi
respons
critic
develop
vaccin
bacteri
infect
level
antibodi
produc
tpav
construct
compar
report
effect
protein
vaccin
formul
contain
lcrv
moreov
protect
afford
tpav
dna
vaccin
compar
report
lcrv
proteinbas
vaccin
moder
inferior
report
twocompon
protein
formul
test
pesti
mous
respiratori
infect
model
previou
studi
use
lcrv
protein
alon
report
protect
ld
fusion
protein
induc
protect
challeng
dose
compar
protect
observ
tpav
highest
challeng
dose
ld
twocompon
formul
protect
achiev
ld
anoth
studi
report
protect
ld
subunit
vaccin
reflect
variat
differ
experiment
system
aerosol
infect
use
pneumon
plaqu
studi
use
intranas
rout
rout
could
yield
acut
pneumonia
rapid
develop
system
infect
appear
produc
compat
ld
valu
given
mous
strain
similar
mean
time
death
given
similar
pattern
diseas
unlik
challeng
rout
major
influenc
outcom
protect
studi
addit
tpa
leader
sequenc
lcrv
gene
play
crucial
role
achiev
good
protect
prove
antigen
engin
afford
strong
potenti
develop
effect
dna
vaccin
bacteria
includ
thoselik
pestisar
primarili
extracellular
pathogen
shown
result
tpa
leader
tpav
construct
enhanc
protein
product
result
lcrv
antigen
modifi
structur
featur
indic
tendenc
form
oligom
oligom
lcrv
antigen
associ
enhanc
immunogen
observ
proteinbas
v
formul
studi
need
elucid
mechan
tpav
construct
stronger
tendenc
form
oligomer
v
wtv
construct
leader
sequenc
may
affect
fold
secret
protein
previous
report
addit
tpav
induc
greater
level
respons
wtv
indic
enhanc
h
prefer
lcrv
recent
report
induc
high
level
product
mechan
involv
direct
interact
lcrv
import
effect
vivo
yet
firmli
establish
data
concern
effect
develop
lcrvspecif
immun
given
fact
inhibit
h
immun
respons
like
tpav
may
less
effect
wtv
induc
due
reduc
abil
interact
bia
toward
effect
h
respons
pesti
basi
enhanc
immunogen
protect
afford
tpav
focu
current
studi
mechan
mention
may
contribut
concert
studi
need
examin
exact
process
tpav
induc
better
protect
dna
vaccin
express
antigen
yield
partial
protect
lethal
mucos
challeng
confirm
result
vaccin
studi
use
recombin
protein
candid
vaccin
addit
tpa
leader
improv
level
protect
surpris
given
fact
nativ
signal
sequenc
support
secret
find
consist
experi
addit
extra
signal
sequenc
wild
type
gene
improv
immunogen
dna
vaccin
studi
dna
vaccin
express
pla
antigen
provid
protect
pla
gene
unusu
hydrophob
sequenc
near
nterminu
may
respons
poor
express
solubl
pla
antigen
thu
poor
immunogen
pla
dna
vaccin
interest
see
pla
antigen
achiev
better
protect
ntermin
hydrophob
sequenc
remov
result
indic
properli
design
dna
vaccin
offer
effect
protect
highli
virul
extracellular
bacteri
pathogen
vaccin
use
alon
also
compon
dna
prime
plu
protein
boost
formul
combin
offer
mani
advantag
convent
singl
modal
vaccin
dna
protein
individu
effect
induc
differ
set
immun
respons
proteinbas
vaccin
effect
induc
high
antibodi
respons
multipl
inocul
strong
adjuv
usual
requir
use
dna
compon
prime
phase
significantli
reduc
amount
protein
need
boost
decreas
number
protein
immun
requir
induc
level
protect
immun
respons
dna
also
stabl
easier
manufactur
recombin
protein
dna
vaccin
proven
extrem
safe
clinic
studi
conduct
date
eas
modif
encod
antigen
express
conformationsensit
antigen
vivo
circumv
lengthi
expens
process
vitro
protein
product
import
advantag
offer
dna
vaccin
technolog
particularli
light
emerg
infecti
diseas
threat
bioterror
rapid
develop
robust
vaccin
may
becom
frequent
requir
potenti
dna
vaccin
bacteri
pathogen
warrant
thorough
investig
